# Spravato REMS Requirements and Forms for Treatment Centers

> What the Spravato REMS asks of an outpatient treatment center: certification, 2+ hour monitoring, patient enrollment, forms, scheduling and ad rules.

*Source: https://fillthelobby.com/blog/spravato-rems-requirements*

## Spravato REMS requirements: what a treatment center has to do

Under the Spravato REMS requirements, an outpatient treatment center must be certified before ordering, enroll every patient before the first dose, have a prescriber onsite during dosing and monitoring, monitor each patient for at least two hours with pulse oximetry, and file a Patient Monitoring Form within 7 calendar days of every dose. Fill The Lobby is a marketing company, not a REMS consultant.

By [Ghazanfar Idrees](https://fillthelobby.com/about#ghazanfar-idrees), Co-founder & COO · Updated 28 September 2026 · 9 min read

The Spravato REMS requirements decide who can give esketamine and how. An outpatient clinic has to be certified before it can order Spravato, enroll each patient before the first dose, have a prescriber onsite, and monitor every patient for at least two hours after every dose. None of it is optional, and all of it shapes how you schedule and market the service.

This guide covers the outpatient version: certification, what happens at each visit, and what the rules mean for your calendar, your booking page and your ads.

## What is the Spravato REMS?

A REMS (Risk Evaluation and Mitigation Strategy) is a safety program the FDA requires for some drugs. Spravato is available only through one, because of the risks of sedation, dissociation and respiratory depression after a dose, and of abuse and misuse. It is never dispensed for home use.

Janssen, the drug's maker, runs the program. Settings enroll and submit forms online through [the Spravato REMS website](https://www.spravatorems.com/) or by fax, and the helpline is 1-855-382-6022. The FDA's [REMS listing for Spravato](https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=386) shows the program was first approved in March 2019 and last modified on 24 June 2026, a change to the website's workflows (checked 15 September 2026).

The requirements below come from the [REMS document](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_REMS_Document.pdf) and [program overview](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_REMS_Program_Overview.pdf) the FDA published with that change. Read them yourself before you enroll. This guide is a map, not legal advice.

## How to become a Spravato treatment center

Certification belongs to the setting, not to an individual clinician. For an outpatient medical office or clinic, the REMS document sets out these steps:

1. Have the people and equipment in place. A prescriber onsite during administration and monitoring, healthcare providers to monitor patients onsite, and a pulse oximeter.
2. Name an authorized representative. This person carries out certification and oversees compliance for the setting.
3. Read the source documents. The representative reviews the Spravato prescribing information and the REMS Program Overview.
4. Enroll the setting. The representative completes the [Outpatient Healthcare Setting Enrollment Form](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_Outpatient_Healthcare_Setting_Enrollment_Form.pdf), which asks for the DEA license number tied to the setting's address, and submits it to the REMS.
5. Write the processes and train the staff. Procedures for enrolling patients, counseling them, checking enrollment before each dose and submitting monitoring forms, with training for everyone involved in prescribing, dispensing and administering.

Once the form is in, the REMS notifies you of certification and tells you the further requirements for ordering and receiving Spravato. Certification then has upkeep: training records, records of every shipment and every dose given, audits by Janssen or someone acting for it, and a new enrollment form if your authorized representative changes.

## Spravato REMS requirements for every patient visit

Once you're certified, the rules move to the patient. This is the sequence the REMS document and overview set out for outpatients:

| When | What the REMS requires |
| --- | --- |
| Before the first dose | A healthcare provider counsels the patient on the risks, the monitoring and the need to arrange a safe way to leave. A prescriber enrolls the patient with the Patient Enrollment Form. |
| Before every dose | Counsel the patient on monitoring again, and verify they are enrolled. |
| During and after every dose | The patient self-administers under the direct supervision of a healthcare provider. A healthcare provider monitors for sedation, dissociation, respiratory depression and other changes in vital signs, using pulse oximetry, for at least two hours and until those effects resolve. |
| Within 7 calendar days | Submit a Patient Monitoring Form for that dose. |
| Before a transfer | Tell the REMS in advance if the patient's treatment moves to another certified setting. |

The two hours are a floor. The REMS requires monitoring until those effects resolve, and the [Spravato prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed) adds an assessment after monitoring to decide when the patient is clinically stable and ready to leave.

## Spravato REMS forms: which one, who, and when

Three forms carry most of the paperwork. Each has a different owner and a different deadline, so it helps to see them side by side:

| Form | Who completes it | When |
| --- | --- | --- |
| [Outpatient Healthcare Setting Enrollment Form](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_Outpatient_Healthcare_Setting_Enrollment_Form.pdf) | The setting's authorized representative | Once, to certify the setting, and again by a new authorized representative if the current one leaves |
| [Patient Enrollment Form](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_Patient_Enrollment_Form.pdf) | A prescriber | Before the patient's first dose |
| Patient Monitoring Form | The certified setting | Within 7 calendar days of every dose |

The monitoring form is the one that recurs, so it belongs in the visit workflow rather than on someone's end-of-week list.

## What the rules do to your schedule

The REMS sets the length of a visit. The label sets how often visits happen. For treatment-resistant depression in adults, [the recommended schedule](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed) is twice a week in weeks one to four, once a week in weeks five to eight, then every two weeks or weekly after that, with the later frequency set per patient.

Put those together and the constraint is plain. Under the label's recommended schedule, a new patient starts with two monitored visits a week for the first four weeks, each at least two hours long, with a prescriber onsite. Your capacity is set by monitoring space and staff, not by how many people ask.

That matters for marketing. If new inquiries outpace the monitored chairs you have for the first month, you get a waitlist, not a fuller schedule. Pace new starts against the chairs you have, and keep in touch with anyone waiting. That second part is what [patient follow-up](https://fillthelobby.com/services/patient-follow-up) is for.

## What patients need to know before they book

Several REMS and label requirements land on the patient. Say them before anyone takes a slot:

- Time. At least two hours onsite after each dose, plus the check before leaving.
- Transport. [The label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed) says not to drive or operate machinery until the next day after a restful sleep, so patients need a ride home.
- Frequency. Twice-weekly visits for the first month under the label's schedule for treatment-resistant depression.
- Enrollment. Every outpatient is enrolled in the REMS, on a form completed with a healthcare provider.

These belong on your [booking page](https://fillthelobby.com/services/booking-pages), in plain words, next to the button. Someone who can't manage the rides or the schedule should find out there, not at the consult. If you also send ad traffic to that page, the Google rules in the advertising section below apply to it.

One thing does not belong there: clinical detail. The [Patient Enrollment Form](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_Patient_Enrollment_Form.pdf) asks the prescriber for pre-existing conditions and current medications. That is clinical intake, done with a provider. A website or ad lead form should take contact details and a preferred time, and no health information.

## Certification is not permission to advertise

REMS certification lets you order and give Spravato. It doesn't cover your ads.

- Google. Its [Healthcare and medicines policy](https://support.google.com/adspolicy/answer/176031) restricts prescription drug terms in ads, landing pages and keywords. In the US, only online pharmacies accredited by LegitScript or NABP and telemedicine providers accredited by LegitScript may promote prescription drugs, and they must also be certified with Google (checked 15 September 2026). An in-office treatment center is not one of the listed categories, so check with Google before you put Spravato in an ad, keyword or landing page.
- Meta. Its [drugs and pharmaceuticals ad standards](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/) allow prescription drug ads from online pharmacies and telehealth providers certified with LegitScript, and from pharmaceutical manufacturers, which can use LegitScript certification or Meta's own review. All need Meta's authorization; none may target under-18s. Ads that only educate about prescription drugs don't need written authorization (checked 15 September 2026).
- The FTC. Its [Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance) says health claims need competent and reliable scientific evidence, and that individual consumers' experiences are never enough to back one up (checked 15 September 2026).

The REMS doesn't approve ads, and ad approval doesn't cover the REMS. They are two separate checks.

## Keep Spravato and IV ketamine claims apart

If you offer both, treat them as two services. To a regulator they are different products.

[Spravato's label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed) indicates it for treatment-resistant depression in adults, alone or with an oral antidepressant, and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, alongside an oral antidepressant. The same label says its effectiveness in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.

Ketamine is another matter. In a [warning letter dated 23 June 2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ketamine-store-wwwketaminestoreorg-725147-06232026), the FDA restated that ketamine is approved as an injectable general anesthetic and is not FDA-approved for the treatment of any psychiatric disorder.

Don't let an IV ketamine page borrow Spravato's approval. "FDA-approved" belongs next to Spravato and its labeled uses only, and the Spravato REMS covers Spravato, not ketamine infusions.

We don't certify settings or complete REMS forms. How we hold ad and landing page to one claim set, and run Spravato and IV ketamine as separate campaigns, is on our [ketamine and Spravato clinic marketing](https://fillthelobby.com/ketamine-spravato-marketing) page.

## Sources

- [FDA — REMS@FDA: Spravato (esketamine) REMS listing and modification history](https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=386), checked 15 September 2026
- [FDA — Spravato REMS document, updated June 2026](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_REMS_Document.pdf), checked 15 September 2026
- [FDA — Spravato REMS Program Overview, as posted with the 24 June 2026 modification](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_REMS_Program_Overview.pdf), checked 15 September 2026
- [FDA — Spravato REMS Patient Enrollment Form, outpatient use](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_Patient_Enrollment_Form.pdf), checked 15 September 2026
- [FDA — Spravato REMS Outpatient Healthcare Setting Enrollment Form](https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_Outpatient_Healthcare_Setting_Enrollment_Form.pdf), checked 15 September 2026
- [DailyMed (National Library of Medicine) — Spravato (esketamine) nasal spray prescribing information, revised March 2026](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed), checked 15 September 2026
- [Janssen — Spravato REMS program website](https://www.spravatorems.com/), checked 15 September 2026
- [FDA — Warning letter 725147, 23 June 2026 (ketamine approval status)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ketamine-store-wwwketaminestoreorg-725147-06232026), checked 15 September 2026
- [Google Ads Help — Healthcare and medicines policy](https://support.google.com/adspolicy/answer/176031), checked 15 September 2026
- [Meta Transparency Center — Drugs and pharmaceuticals ad standards](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/), checked 15 September 2026
- [FTC — Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance), checked 15 September 2026

## Spravato REMS: quick answers.

**Q: What is the Spravato REMS?**

A Risk Evaluation and Mitigation Strategy: a safety program the FDA requires for Spravato because of the risks of sedation, dissociation, respiratory depression, abuse and misuse. Janssen runs it, and a setting must be certified and each patient enrolled before Spravato is given there.

**Q: How is Spravato administered?**

As a nasal spray the patient self-administers at a REMS-certified healthcare setting, under the direct supervision of a healthcare provider. The patient is then monitored for at least two hours and until sedation, dissociation and changes in vital signs resolve. Spravato is never dispensed for home use.

**Q: How often is Spravato given?**

For treatment-resistant depression in adults, the prescribing information recommends twice a week in weeks one to four, once a week in weeks five to eight, then weekly or every two weeks, with the later frequency set per patient. Every dose needs its own monitored visit.

**Q: Who can prescribe Spravato?**

Under the REMS, certification belongs to the healthcare setting, not to an individual clinician. A prescriber enrolls each patient before the first dose, and a prescriber has to be onsite at the certified setting during administration and monitoring.

**Q: Is Spravato the same as ketamine?**

No. Spravato is esketamine, a nasal spray available only through its REMS at certified settings. The FDA says ketamine itself is not approved for any psychiatric disorder, so clinics offering both should keep the two services, and what they say about each, separate.

**Q: Does the Spravato REMS apply to IV ketamine clinics?**

No. The REMS covers Spravato, the esketamine nasal spray. The FDA says ketamine is not approved for any psychiatric disorder, so clinics offering both should keep the two services and their claims separate.

**Q: Does a prescriber have to be onsite for the whole visit?**

Yes, for dosing and monitoring. The REMS document requires a prescriber onsite during Spravato administration and monitoring, and healthcare providers onsite to monitor each patient for at least two hours after every dose.

**Q: Which forms does the Spravato REMS require?**

Three carry most of the work: the Outpatient Healthcare Setting Enrollment Form, completed once by the authorized representative to certify the setting; the Patient Enrollment Form, completed by a prescriber before the first dose; and the Patient Monitoring Form, submitted within 7 calendar days of every dose.

**Q: How soon does the Patient Monitoring Form have to be submitted?**

Within 7 calendar days after each dose. The REMS also expects the setting to have processes and trained staff in place to do this every time.

**Q: Can a patient drive home after a Spravato session?**

No. The prescribing information says patients should not drive or operate machinery until the next day after a restful sleep, so they need to arrange a ride home.

**Q: What happens if our authorized representative leaves?**

A new authorized representative has to enroll by completing the Outpatient Healthcare Setting Enrollment Form for the setting to keep its certification.

**Q: What if a patient moves their treatment to another clinic?**

Tell the Spravato REMS in advance. The REMS Program Overview requires notice whenever a patient's treatment transfers from one REMS-certified healthcare setting to another.

Reviewed September 2026.

## Keep reading.

## Marketing Spravato inside the rules?

## Related pages

- [Blog](https://fillthelobby.com/blog)
- [patient follow-up](https://fillthelobby.com/services/patient-follow-up)
- [booking page](https://fillthelobby.com/services/booking-pages)
- [ketamine and Spravato clinic marketing](https://fillthelobby.com/ketamine-spravato-marketing)
- [Ketamine and Spravato clinic marketing](https://fillthelobby.com/ketamine-spravato-marketing)
- [Psychiatry practice marketing](https://fillthelobby.com/psychiatry-practice-marketing)
- [How we handle compliance](https://fillthelobby.com/compliance)
- [What is AI visibility, and how do you audit it for your practice?](https://fillthelobby.com/blog/ai-visibility-audit)
- [AI in healthcare marketing: what a private practice can use now](https://fillthelobby.com/blog/ai-in-healthcare-marketing)
- [Book a 30-minute call](https://fillthelobby.com/book)